Lilly defends Zyprexa's U.K. exclusivity; China mulls mandatory licensing on AIDS meds;

@FiercePharma: Medicare won't drop Avastin for breast cancer. Item | Follow @FiercePharma

> Eli Lilly, whose biggest-selling schizophrenia medicine Zyprexa survived a patent challenge in Britain two years ago, asked a U.K. judge to reject a parallel lawsuit by a closely held generics company. News

> Shire sued the Novartis generics unit Sandoz and generics maker Amneal Pharmaceuticals to challenge copycat versions of its top-selling ADHD drug Vyvanse. Item

> China may turn to mandatory licensing to secure cheaper drugs for HIV/AIDS patients as the nation's health authority prepares to expand coverage. Article

> The EMA has given pharma companies new, highly-specific electronic formats in which they will soon have to submit information on medicines authorised or registered in the EU. Report

> Reports of potentially misleading pharmaceutical pitches increased threefold from the previous year after the FDA launched its Bad Ad Program. Item

> U.K. Health Secretary Andrew Lansley said Britain needs to overhaul the way it funds care for the elderly, as he awaited the publication of a report that may recommend capping the amount older citizens have to pay. Story

> An Indian inter-ministerial group has suggested that the foreign direct investment cap in existing pharmaceutical ventures be lowered to 49 percent from 100 percent to check takeover of local companies by multinationals. News

> Glenmark Pharmaceuticals said it settled patent litigation with Daiichi Sankyo and Genzyme over its proposed generic version of the diabetes drug Welchol, in a deal allowing it to launch its product by April 2, 2015. Piece

> GlaxoSmithKline has signed a deal with the World Anti-Doping Agency to help scientists develop early detection methods for drugs that have performance-enhancing potential in sport. News

Biotech News

 @FierceBiotech: Merck cuts 51 jobs as it closes Inspire site. Story | Follow @FierceBiotech

@JohnCFierce: Novartis halts Afinitor breast cancer study on positive data; preps new app for blockbuster market. Article | Follow @JohnCFierce

> Scientist explores the possibility of cheating death "indefinitely." News 

> J&J gets FDA green light for blockbuster blood thinner Xarelto. Story

> Novartis wins FDA OK of low-dose COPD therapy. Item 

Manufacturing News

> McKesson VP reveals secret to meeting distribution challenges. News

> Baxter beats environmental goals in 2010. Item

> For PwC, ops and business strengths drive PRTM buy. Article

> Vax industry braces as China nears global manufacturer status. Item 

> Republicans question drugmakers in heparin probe. Report 

> How MIT's Hockfield can drive a pharma manufacturing makeover. Story

Biotech IT

> MD credibility helps convert social media users to trial volunteers. Item 

> Google Health going out with a whimper. News

> Open-source start-up TLS lands seed funding. Report

> Hackers, some helpful, penetrate big-name pharma and healthcare. Article

> IBM, others herd trial data to cloud. Item 

> India trains IT savvy on drug trials, safety. News

Biotech Research News

> Brain stem cells are fruitful and multiply. Item 

> Autism experts skeptical of study linking disorder to environment. Report

> Scientists crack histamine code that could lead to better allergy relief. News

And Finally... By sensing emotions that we would otherwise miss, new "social X-ray specs" are set to transform how we interact with each other. Report

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.